Summary
Merck & Co., Inc. (MRK) filed an 8-K on July 27, 2015, detailing significant changes to its Board of Directors and corporate governance. The filing announced the election of Pamela J. Craig and Paul B. Rothman, M.D., to the Board, effective September 1, 2015. Ms. Craig will join the Audit Committee and Dr. Rothman will be part of the Research Committee. Their compensation will align with standard non-employee director practices. Crucially, the company also amended its By-Laws to implement 'proxy access.' This new provision allows eligible long-term shareholders (holding at least 3% for three years) to nominate a limited number of directors (up to 20% of the Board) to be included in Merck's proxy materials, starting with the 2016 Annual Meeting. These changes signal Merck's responsiveness to shareholder governance demands and enhance the mechanisms for board-level oversight and shareholder participation.
Key Highlights
- 1Election of Pamela J. Craig and Paul B. Rothman, M.D., to the Board of Directors, effective September 1, 2015.
- 2Pamela J. Craig appointed to the Audit Committee.
- 3Paul B. Rothman, M.D., appointed to the Research Committee.
- 4Adoption of 'proxy access' by amending By-Laws, effective July 22, 2015.
- 5Proxy access allows eligible shareholders (3% ownership for 3+ years) to nominate up to 20% of directors for inclusion in proxy statements.
- 6Proxy access provision first applicable for the 2016 Annual Meeting of Shareholders.
- 7Updates to advance notice requirements for shareholder proposals and director nominations, and modifications to indemnification provisions.